Mannitol

Global Sugar Alcohols Strategic Research Report 2023-2024 & 2030 - Exploding Demand for Food Additives Triggers Massive Opportunities - ResearchAndMarkets.com

Retrieved on: 
torsdag, maj 16, 2024
Food, Beverage, Retail, Growth, Sugar, Sorbitol, Sugar alcohol, Mannitol, Alcohol (chemistry)

The "Sugar Alcohols - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sugar Alcohols - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.
  • The global sugar alcohols market is experiencing steady growth, driven by their use across diverse sectors, generating sustained opportunities.
  • Growing awareness about the benefits offered by sugar alcohols is enhancing their appeal and image as sugar-free sweeteners.
  • Sugar alcohols have gained popularity as alternatives to sugar, particularly in regions with increasing health consciousness.

The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study

Retrieved on: 
onsdag, oktober 25, 2023
Osteoporosis, Safety, Injection, Mannitol, Doctor of Philosophy, Teriparatide, Starch, GLP, SAN, Animal, Pharmaceutical industry

SAN JOSE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced preclinical data supporting the safety and tolerability of the RaniPill® drug delivery platform following 60-day repeat administration. In the 60-day good laboratory practices (“GLP”) study in healthy animals, the RaniPill® capsule was well-tolerated with no treatment-related adverse events.

Key Points: 
  • SAN JOSE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced preclinical data supporting the safety and tolerability of the RaniPill® drug delivery platform following 60-day repeat administration.
  • In the 60-day good laboratory practices (“GLP”) study in healthy animals, the RaniPill® capsule was well-tolerated with no treatment-related adverse events.
  • “The preclinical data announced today are highly encouraging and we believe these data further validate the safety and tolerability of our RaniPill® drug delivery platform,” said Mir Hashim, PhD, Chief Scientific Officer of Rani.
  • RT-100 was well-tolerated with no treatment-related adverse events and all animals remained clinically healthy throughout the study.

Global Polyol Sweeteners Strategic Market Report 2023: A $7.5+ Billion Market by 2030 - Focus on Sorbitol, Xylitol, Mannitol, Maltitol, Isomalt - ResearchAndMarkets.com

Retrieved on: 
fredag, september 15, 2023
Food, Beverage, Retail, Real, Xylitol, Personal care, Cosmetics, Growth, Isomalt, Polyol, Pharmaceutical industry, Video game, Sorbitol, Mannitol, Maltitol

The global market for Polyol Sweeteners is undergoing significant growth, with the industry expected to flourish in the coming years.

Key Points: 
  • The global market for Polyol Sweeteners is undergoing significant growth, with the industry expected to flourish in the coming years.
  • Independent analysis reveals substantial market potential across various geographic regions, offering valuable insights into past, present, and future trends.
  • With applications ranging from Food & Beverage to Personal Care & Cosmetics, Pharmaceuticals, and more, the Polyol Sweeteners market is poised for impressive growth.
  • The Polyol Sweeteners market in the U.S. is estimated at US$1.2 Billion in the year 2022.

Ivy Brain Tumor Center Opens Novel Clinical Trial to Test Direct-to-Tumor Drug Delivery Method

Retrieved on: 
tisdag, juli 18, 2023
Glioma, Brain, Ben, Wrist, Clinical trial, Traffic barrier, Catheter, Mannitol, Glioblastoma, Blood, Barrow Neurological Institute, MD, Patient, Hedera, Neoplasm, Pharmaceutical industry, Medical imaging

SSIAI is a novel technique that can deliver a highly-concentrated dose of experimental drug directly to the brain tumor while minimizing systemic side effects.

Key Points: 
  • SSIAI is a novel technique that can deliver a highly-concentrated dose of experimental drug directly to the brain tumor while minimizing systemic side effects.
  • “Drug delivery is arguably the most significant problem in brain tumor treatment today,”  says Nader Sanai, MD, Director of the Ivy Brain Tumor Center and Director of Neurosurgical Oncology at Barrow Neurological Institute.
  • Additional clinical trial information can be found at NCT05773326 or the Ivy Brain Tumor Center’s website .
  • The Ivy Brain Tumor Center at Barrow Neurological Institute facilitates the largest early-phase drug development program for brain cancer.

Global Anodic Aluminium Oxide Wafer Market Report 2022: Increased Usage Of AAO Template For Making MEMs Devices Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
tisdag, januari 24, 2023
Pharmaceutical, Other Manufacturing, Health, Medical Devices, Consumer Electronics, Technology, Semiconductor, Manufacturing, Mannitol, Memory, Glycine, Electronics, Radio, RFIC, Gelatin, Growth, Microelectromechanical systems, AAO, Personal computer, HPC, Aluminium

The Global Anodic Aluminium Oxide Wafer Market size is expected to reach $254.8 Million by 2028, rising at a market growth of 21.0% CAGR during the forecast period.

Key Points: 
  • The Global Anodic Aluminium Oxide Wafer Market size is expected to reach $254.8 Million by 2028, rising at a market growth of 21.0% CAGR during the forecast period.
  • The ability of AAO template to help manufacture MEMs devices will boost the anodic aluminum oxide wafer market.
  • On the basis of wafer type, the anodic aluminum oxide wafer market is divided into 6-inch, 8-inch, 12-inch and others.
  • The pharmaceutical segment recorded a remarkable growth rate in the anodic aluminum oxide wafer market in 2021.

Global Anodic Aluminium Oxide Wafer Market Report 2022: Sector to Reach $254.8 Million by 2028 at a 21% CAGR

Retrieved on: 
onsdag, januari 25, 2023
Glycine, HPC, Microelectromechanical systems, Radio, Electronics, Mannitol, Growth, Memory, AAO, RFIC, Gelatin, Personal computer, Aluminium

The Global Anodic Aluminium Oxide Wafer Market size is expected to reach $254.8 Million by 2028, rising at a market growth of 21.0% CAGR during the forecast period.

Key Points: 
  • The Global Anodic Aluminium Oxide Wafer Market size is expected to reach $254.8 Million by 2028, rising at a market growth of 21.0% CAGR during the forecast period.
  • The ability of AAO template to help manufacture MEMs devices will boost the anodic aluminum oxide wafer market.
  • On the basis of wafer type, the anodic aluminum oxide wafer market is divided into 6-inch, 8-inch, 12-inch and others.
  • The 12-inch segment witnessed the largest revenue share in the anodic aluminum oxide wafer market in 2021.

Global Food Sweetener Market Report 2022 to 2027: Industry Trends, Share, Size, Growth, Opportunities and Forecasts - ResearchAndMarkets.com

Retrieved on: 
torsdag, november 24, 2022
Food, Beverage, Retail, Taste, Prevalence, Investment, Erythritol, R, Starch, Honey, Stevia, Food, Fermentation, Sucrose, F&B, Ice cream, Obesity, Tooth decay, Research, Drink, Meal, Degenerative disease, Diabetes, COVID-19, Xylitol, Yogurt, Mannitol, Maple syrup, Soft drink

Food sweetener refers to a food additive that imparts sweet taste in various meals and beverages with the support of preservation, fermentation, baking, and caramelization techniques.

Key Points: 
  • Food sweetener refers to a food additive that imparts sweet taste in various meals and beverages with the support of preservation, fermentation, baking, and caramelization techniques.
  • Other factors, such as strategic collaborations amongst the key players and the rising investments in research and development (R&D) activities are creating a positive outlook for the global food sweetener market.
  • This report provides an analysis of the key trends in each sub-segment of the global food sweetener market, along with forecasts at the global, regional and country level from 2022-2027.
  • The report has categorized the market based on product type, application and distribution channel.

Akorn Introduces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg at ASRM

Retrieved on: 
torsdag, oktober 27, 2022
Projection, Reproductive medicine, Mannitol, Review, Merck Group, ASRM, Assisted reproductive technology, Industry, FDA, Patient, Company, Injection, Fertilisation, Nasal spray, CGT, Gonadotropin-releasing hormone, ART, Luteinizing hormone, Society, Conference, Multimedia, Akorn, Egg, Merck, Menstrual cycle, Allergy, Merck Serono, Ovulation, Pharmaceutical industry, Birth control, IQVIA, Cetrorelix

GURNEE, Ill., Oct. 27, 2022 /PRNewswire/ -- Akorn Operating Company LLC, a specialty pharmaceutical company, is launching the first to market generic Cetrorelix Acetate for Injection 0.25 mg (Cetrorelix) at the 2022 American Society for Reproductive Medicine Conference (ASRM) Conference in Anaheim, California. ASRM brings together leading medical professionals to discover the latest in reproductive medicine, treatments, and patient management. Cetrorelix is the first approved, AP–rated and bioequivalent version of EMD Serono's Cetrotide®.1

Key Points: 
  • GURNEE, Ill., Oct. 27, 2022 /PRNewswire/ -- Akorn Operating Company LLC, a specialty pharmaceutical company, is launching the first to market generic Cetrorelix Acetate for Injection 0.25 mg (Cetrorelix) at the 2022 American Society for Reproductive Medicine Conference (ASRM) Conference in Anaheim, California.
  • Cetrorelix is the first approved, APrated and bioequivalent version of EMD Serono's Cetrotide.1
    "We are pleased to introduce Cetrorelix to attendees at the ASRM conference," says Akorn President and CEO Douglas Boothe.
  • The FDA granted Akorn a Competitive Generic Therapy (CGT) designation for Cetrorelix, a designation intended to incentivize effective development, efficient review, and timely market entry of drugs for which there is inadequate generic competition.
  • Do not use Cetrorelix if you:
    are allergic to cetrorelix acetate, mannitol or exogenous peptide hormones (medicines similar to cetrorelix acetate for injection); or
    are pregnant, or think that you might be pregnant, or if you are breastfeeding.

Y Combinator-backed Kiwi Biosciences Launches Novel Portable Enzymes To Make Food Painless For 15% of the Planet

Retrieved on: 
onsdag, augusti 31, 2022
Enzyme, Garlic, Y Combinator, Lactase, Monash University, Mannitol, Harvard Innovation Labs, Alpha-galactosidase, Sorbitol, Harvard University, Medicine, Lactose, Biotechnology, FODMAP, IBS, Fructan, United Kingdom, Sugar, MPH, Gastrointestinal disease, Irritable bowel syndrome

CAMBRIDGE, Mass., Aug. 31, 2022 /PRNewswire/ -- Kiwi Biosciences, the Y Combinator-funded biotech startup making food painless, launches the next generation FODZYME , a novel patent-pending enzyme supplement helping people enjoy their favorite foods, wherever they are.

Key Points: 
  • CAMBRIDGE, Mass., Aug. 31, 2022 /PRNewswire/ -- Kiwi Biosciences, the Y Combinator-funded biotech startup making food painless, launches the next generation FODZYME , a novel patent-pending enzyme supplement helping people enjoy their favorite foods, wherever they are.
  • These compounds, called FODMAPs, are particularly problematic for people with Irritable Bowel Syndrome (IBS), which affects 15% of the global population.
  • Backed by Y Combinator , Kiwi Biosciences is a human-centered biotech company creating elegant scientific solutions for extraordinary gut relief.
  • On a mission to make food painless, Kiwi Biosciences is working on a polyol-targeting formulation and advancing novel enzyme technologies to address all FODMAPs.

Akorn Announces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg

Retrieved on: 
tisdag, augusti 16, 2022
FDA, Woman, Mannitol, Merck Group, Menstrual cycle, Multimedia, Luteinizing hormone, Nasal spray, Industry, Akorn, Ovulation, Pregnancy, Gonadotropin-releasing hormone, Merck, Merck Serono, Fertilisation, Review, Egg, Company, Fertility, Allergy, View, ART, Projection, AP, EMD, CGT, Injection, Pharmaceutical industry, Birth control, IQVIA, Cetrorelix

GURNEE, Ill., Aug. 16, 2022 /PRNewswire/ -- Akorn Operating Company LLC, a specialty pharmaceutical company, announces that it received FDA approval for a generic version of Cetrorelix Acetate for Injection, 0.25 mg (Cetrorelix).

Key Points: 
  • GURNEE, Ill., Aug. 16, 2022 /PRNewswire/ -- Akorn Operating Company LLC, a specialty pharmaceutical company, announces that it received FDA approval for a generic version of Cetrorelix Acetate for Injection, 0.25 mg (Cetrorelix).
  • 2
    The FDA granted Akorn a Competitive Generic Therapy (CGT) designation for Cetrorelix, a designation intended to incentivize effective development, efficient review, and timely market entry of drugs for which there is inadequate generic competition.
  • Cetrorelix Acetate for Injection blocks such undesirable premature ovulation.
  • Do not use Cetrorelix Acetate for Injection if you:
    are allergic to cetrorelix acetate, mannitol or exogenous peptide hormones (medicines similar to cetrorelix acetate for injection); or
    are pregnant, or think that you might be pregnant, or if you are breastfeeding.